Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
56 stopped studies mapped to Gliosarcoma and descendants · 84% state a reason
Over the 56 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06806228 | Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard… | Phase 1 | suspended | Feb 4, 2025 | Petrov, Andrey | The study protocol will be changed | Other (stated, no rule matched) |
| NCT05091866 | Natural Progesterone for the Treatment of Recurrent Glioblastoma | Early Phase 1 | terminated | Oct 25, 2021 | Emory University | Review of Drug Supply | Drug supply |
| NCT02942264 | Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized… | Phase 1 / Phase 2 | terminated | Oct 24, 2016 | National Cancer Institute (NCI) | Unable to supply investigational agent, Zotiraciclib (TG02). | Drug supply |
| NCT03107780 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain… | Phase 1 | terminated | Apr 11, 2017 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in… | Phase 1 | terminated | Sep 8, 2011 | M.D. Anderson Cancer Center | \<75 % participant accrual | Enrollment / accrual |
| NCT01814813 | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With… | Phase 2 | terminated | Mar 20, 2013 | Alliance for Clinical Trials in Oncology | DSMB futility analysis | Efficacy / futility |
| NCT04397679 | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly… | Phase 1 | terminated | May 21, 2020 | Barbara Ann Karmanos Cancer Institute | slow accrual | Enrollment / accrual |
| NCT03973918 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG(BRAF) | Phase 2 | terminated | Jun 4, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer | Other (stated, no rule matched) |
| NCT02133183 | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | Phase 1 | terminated | May 7, 2014 | National Cancer Institute (NCI) | Other - Lapse in funding | Funding |
| NCT02168270 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | Phase 1 | terminated | Jun 20, 2014 | University of Nebraska | not stated | Not stated |
| NCT01721577 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas(AXL1717) | Phase 1 / Phase 2 | terminated | Nov 5, 2012 | Rush University Medical Center | Investigator went to another institution. | Investigator |
| NCT02664363 | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma(ExCeL) | Phase 1 | terminated | Jan 27, 2016 | Daniel Landi | Study funding ended | Funding |
| NCT01822275 | Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and…(GCC 1224) | Phase 2 | terminated | Apr 2, 2013 | University of Maryland, Baltimore | Poor accrual | Enrollment / accrual |
| NCT05017610 | Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma | Early Phase 1 | withdrawn | Aug 24, 2021 | Emory University | Per the PI-slow accrual | Enrollment / accrual |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in… | Phase 1 / Phase 2 | terminated | Apr 30, 2008 | Fred Hutchinson Cancer Center | Terminated due to loss in funding. | Funding |
| NCT03641326 | Sunitinib in Sarcomas of the Central Nervous System | Phase 2 | terminated | Aug 22, 2018 | National Cancer Institute (NCI) | Poor accrual | Enrollment / accrual |
| NCT02743078 | Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | Phase 2 | terminated | Apr 19, 2016 | RTOG Foundation, Inc. | Treatment now available commercially | Other (stated, no rule matched) |
| NCT04854044 | ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma | Phase 1 | withdrawn | Apr 22, 2021 | Jonsson Comprehensive Cancer Center | The P.I. is not prepared to move forward at this thime | Other (stated, no rule matched) |
| NCT03283631 | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM(INTERCEPT) | Phase 1 | terminated | Sep 14, 2017 | Gary Archer Ph.D. | We are halting enrollment of this study. | Enrollment / accrual |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or… | Phase 1 | terminated | Oct 2, 2014 | Pediatric Brain Tumor Consortium | Data for the primary objectives is complete and the MTD identified in Stratum II. | Other (stated, no rule matched) |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in… | Phase 2 | withdrawn | Jan 9, 2017 | Jonsson Comprehensive Cancer Center | Final contract negotiations | Other (stated, no rule matched) |
| NCT03843814 | Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma | N/A | terminated | Feb 18, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Imaging results were not sufficient or of good quality; therefore, we will not move further with… | Other (stated, no rule matched) |
| NCT00035373 | Eligibility Screening of Patients With Central Nervous System Tumors for the National… | — | terminated | May 3, 2002 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01186406 | Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed… | Phase 2 | terminated | Aug 23, 2010 | Duke University | Study ended early due to toxicity | Safety / toxicity |
| NCT00734526 | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly… | Phase 1 | terminated | Aug 14, 2008 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01103375 | Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant… | Phase 1 | terminated | Apr 14, 2010 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT01575275 | Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma… | Phase 2 | terminated | Apr 11, 2012 | Michael Vogelbaum, MD, PhD | Drugs unavailable | Other (stated, no rule matched) |
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | Phase 2 | terminated | Apr 22, 2013 | Pediatric Brain Tumor Consortium | Due to several intracranial hemorrhages and recommendation by the PBTC DSMB. | Other (stated, no rule matched) |
| NCT03275558 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | Phase 1 | withdrawn | Sep 7, 2017 | Center Trials & Treatment | Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that… | Enrollment / accrual |
| NCT01086345 | Radiosurgery Plus Bevacizumab in Glioblastoma | Early Phase 1 | terminated | Mar 15, 2010 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01234805 | Yoga Therapy in Treating Patients With Malignant Brain Tumors | N/A | terminated | Nov 4, 2010 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT00112866 | Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive… | Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | due to poor accrual | Enrollment / accrual |
| NCT01122901 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With… | Phase 2 | terminated | May 13, 2010 | National Cancer Institute (NCI) | Stopped prematurely by Company due to decision to terminate all CTEP supplied drug for further… | Sponsor / business decision |
| NCT02194452 | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young… | N/A | withdrawn | Jul 18, 2014 | Sue O'Dorisio | not stated | Not stated |
| NCT01996527 | 3T MRI Biomarkers of Glioma Treatment Response | Early Phase 1 | terminated | Nov 27, 2013 | Vanderbilt-Ingram Cancer Center | PI left institution | Investigator |
| NCT02967380 | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in… | N/A | terminated | Nov 18, 2016 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT02175745 | 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or… | N/A | terminated | Jun 26, 2014 | Erik Mittra | Re-evaluate indication with the referring physicians | Other (stated, no rule matched) |
| NCT01148966 | Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors | Phase 1 | terminated | Jun 23, 2010 | University of Washington | not stated | Not stated |
| NCT02031965 | Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade… | Phase 1 | terminated | Jan 9, 2014 | Pediatric Brain Tumor Consortium | not stated | Not stated |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Aug 13, 2015 | Barbara Ann Karmanos Cancer Institute | Due to lack of funding and a primary co-investigator of the trial leaving the institution. | Investigator |
| NCT01189240 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant… | Phase 1 / Phase 2 | terminated | Aug 26, 2010 | National Cancer Institute (NCI) | Company decided to stop development of drug - 7/31/12 | Sponsor / business decision |
| NCT02599090 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or… | Phase 2 | withdrawn | Nov 6, 2015 | M.D. Anderson Cancer Center | Multi phase study did not progress to Phase II. Phase I registered as NCT00734526. | Other (stated, no rule matched) |
| NCT01227434 | A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma(PD0332991) | Phase 2 | terminated | Oct 25, 2010 | University of California, San Francisco | not stated | Not stated |
| NCT01122888 | Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or… | Phase 1 | terminated | May 13, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01378481 | High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating… | Phase 1 | terminated | Jun 22, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02055196 | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With… | Phase 1 | withdrawn | Feb 5, 2014 | City of Hope Medical Center | New study written | Other (stated, no rule matched) |
| NCT01095094 | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade… | Phase 2 | terminated | Mar 29, 2010 | Case Comprehensive Cancer Center | Study did not meet its primary objective | Other (stated, no rule matched) |
| NCT00735436 | A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | Phase 2 | terminated | Aug 15, 2008 | Duke University | Study enrollment was halted due to slow accrual. | Enrollment / accrual |
| NCT01269411 | RO4929097 in Treating Patients With Recurrent Invasive Gliomas | Phase 1 | terminated | Jan 4, 2011 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00005856 | Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jun 3, 2026source: clinicaltrials